Baird raised the firm’s price target on Bio-Techne (TECH) to $84 from $82 and keeps an Outperform rating on the shares. The firm said they reported FY1Q revenue/EPS ahead of its model, helped by better-than-expected cell and gene therapy performance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
Questions or Comments about the article? Write to editor@tipranks.com